UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

~~WASHINGTON~~Washington, D.C. 20549

FORM 8- K

CURRENT REPORT

Pursuant to Section 13 or 15(d) ~~of the~~

of the Securities Exchange Act of 1934

~~April~~Date of 9,Report ~~2008~~ (~~April~~Date 9,of ~~2008~~earliest event reported): March 26, 2009

Date of Report (Date of earliest event reported)

AVAX TECHNOLOGIES, INC.

(Exact name of ~~Registrant~~registrant as specified in its charter)

Delaware	~~000-29222~~	13000-~~3575874~~29222		13-3575874
(State or other jurisdiction of incorporation)	~~(Commission File Number)~~	(~~IRS~~Commission ~~Employer~~File ~~Identification~~ Number)		(IRS Employer Identification No.)

2000 Hamilton Street

Suite 204

Philadelphia, PA 19130

(Address of principal executive offices and zip code)

Registrant’s telephone number, including area code: (215) 241-9760

~~(Registrant’s telephone number, including area code)~~_____________________________________________________________________________________

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

Item 8.01 Other Events.

OnThe ~~April~~Board of 9Directors of AVAX Technologies, ~~2008~~Inc. (the “Company”), after considering the various ~~company~~options ~~issued~~available ato ~~press~~the ~~release~~Company ~~announcing~~in ~~that~~light of the ~~company~~Company’s financial circumstances, has ~~received~~approved ~~FDA~~a ~~approval~~plan to ~~begin~~deregister ~~enrollment~~the ~~into~~Company's acommon ~~Phase~~stock under ~~I-II~~the ~~clinical~~Securities ~~trial~~Exchange Act of O1934, as amended. Upon filing a Form 15 on or about March 30, 2009, the Company's obligation to file certain reports and forms with the Securities and Exchange Commission (the “SEC”), including Forms 10-~~Vax™~~K, 10-Q and 8-K, will be suspended immediately. The ~~press~~deregistration ~~release~~and termination isof ~~filed~~the Company’s reporting obligations will become effective 90 days after filing, or such shorter period as ~~Exhibit~~the 99SEC may determine.1 The Company reserves the right to ~~this~~postpone ~~report~~or withdraw such filing at any time prior to its effectiveness without further notice. Although the Company will benefit from cost savings as a result of the deregistration, its financial difficulties will remain largely unchanged, and until such time as the Company is able to obtain additional capital it will continue to operate on a very limited basis.

~~Item~~The Company 9has determined that it is necessary to take these steps in order to preserve its limited remaining financial resources for the operation of its business.01 ~~Financial~~The ~~Statements~~Company ~~and~~is ~~Exhibits~~currently negotiating to raise additional capital or secure revenue sources to fund current operations. However, at this time there can be no assurance that the Company will successfully obtain the required capital or revenues, or, if obtained, the amounts will be sufficient to fund ongoing operations in 2009 or thereafter. The inability to secure additional capital will have a material adverse effect on the Company, including the possibility that the Company would have to sell a portion or all of its assets, cease operations or seek bankruptcy relief.

~~(c)~~In ~~Exhibits~~addition, due to the current financial circumstances of the Company, the Board of Directors has decided to temporarily suspend enrollment for its ongoing Phase III Registration, MVALDI trial, M-VAX, for Stage IV melanoma patients.

The following exhibit is filed as part of this report:

Exhibit No.	Description
99.1	AVAX Technologies, Inc. press release issued April 9, 2008.

-1-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned ~~hereunto~~ thereunto duly authorized.

		AVAX TECHNOLOGIES, INC.
Date: March 26, 2009	By:	/s/ Francois R. Martelet, M.D.
Date: April 9, 2008.		By:	/s/	Francois R. Martelet, M.D.
		Name: Francois R. Martelet, M.D.
		Name: Title:		Francois R. Martelet, M.D. President and Chief Executive Officer
		Title: President and Chief Executive Officer

-2-

Filing Compare · AVAX TECHNOLOGIES INC